5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
A critical examination of the UKPDS 34 trial's enrollment biases, statistical caveats, generalizability gaps, and what post-publication commentary revealed about metformin's landmark evidence base.
A deep-dive into the UKPDS 34 trial design, randomization scheme, endpoint definitions, statistical methods, and how each methodological choice shapes the interpretation of metformin's 32% risk reduction in overweight type 2 diabetes.
Deep-dive into the health-economic modeling behind UKPDS 34, examining metformin's cost per QALY, payer-coverage rationale, and real-world pricing for overweight patients with type 2 diabetes.
Complete breakdown of UKPDS 34 metformin outcomes including effect sizes, confidence intervals, secondary endpoints, and the 10-year time-course pattern in overweight type 2 diabetes.
A deep-dive into UKPDS 34, the 1998 landmark trial that proved metformin reduces diabetes complications and death in overweight patients with type 2 diabetes, establishing it as first-line therapy worldwide.